For four straight years, Amphastar Pharmaceuticals ran one of the quieter success stories in generic drugs: revenue nearly doubled, margins tripled, and a well-timed acquisition of a nasal glucagon product called BAQSIMI turned a commodity injectable maker into something that looked almost like a specialty pharma company. Then 2025 arrived, earnings fell sharply, and the stock lost almost all of its twelve-month gains. Now, in the same quarter, the company beat analyst estimates by a wide margin and received two letters from the FDA that no manufacturer wants.
Those two facts should not coexist so comfortably. That tension is the story.
In one breath
The filed numbers show a business that is growing again at the top line, with margins recovering toward their recent peak. The stock trades at roughly half its own decade-median valuation, a gap that implies the market is pricing in something going wrong. The open question is whether two FDA letters, a $100 million milestone payment, and a biosimilar setback are a temporary pile-up or the beginning of a structural squeeze.
What the 8-K changed
On August 6, 2026, Amphastar filed an earnings release alongside a disclosure that reframed the quarter. The company confirmed it had hit a cumulative sales milestone for BAQSIMI, the nasal glucagon it bought from Eli Lilly in 2023. Hitting that milestone sounds like good news. It triggered a $100 million payment back to Lilly, due in the third quarter of 2026. That is more than Amphastar earns in a typical quarter, paid out in a single check.
The same filing disclosed a Complete Response Letter, the FDA’s way of saying “not yet,” for the insulin aspart biosimilar AMP-004. A biosimilar is a near-copy of a biologic drug, the way a generic copies a chemical pill. AMP-004 was the company’s most anticipated near-term launch, targeting a market worth well over a billion dollars. The FDA’s letter does not kill the program, but it pushes the commercial launch to 2027 at the earliest, according to management commentary on the Q2 earnings call.
A third letter, a Warning Letter issued in July 2026 to Amphastar’s subsidiary IMS following a December 2025 manufacturing inspection, adds meaningful remediation costs each quarter, per the same earnings call. That is not a crisis in isolation. Layered on top of the Lilly payment and the biosimilar delay, it means the second half of 2026 carries costs the first half did not.
What the quarterly numbers actually show
Strip the letters away and the 10-Q for the quarter ended June 30, 2026 shows a business in better shape than the annual trend suggests. Revenue reached $183.9 million in Q2, up meaningfully from the same quarter a year earlier, reversing the full-year 2025 decline recorded in the 10-K for fiscal year 2025, when annual revenue slipped and earnings per share fell by roughly a third.
Gross margin, the share of each sales dollar left after manufacturing costs, reached 51% in Q2 2026, a modest improvement over the prior year. That improvement came from new launches: ipratropium bromide, approved in February 2026 and launched in April, contributed meaningfully in its first full quarter. Teriparatide and iron sucrose, both launched in the second half of 2025, added further volume. New products tend to carry better margins than older generics, where competitors have had time to undercut prices, so the mix shift is doing real work here.
R&D spending rose to $22.2 million in the quarter, driven by the insulin pipeline. That is money spent before a product earns a dollar, so rising R&D compresses near-term earnings even when it signals long-term intent.
The math and the mood
“The math” is what the filed fundamentals justify; “the mood” is what the market currently pays. Right now the two are unusually far apart. Amphastar is trading at a price-to-earnings multiple of 11.3, against its own decade median of 19.4 (BullScope valuation model, calculated from trailing-twelve-month GAAP EPS as of June 30, 2026). A company trading at its median multiple would be priced roughly 70% higher than it is today.
The mood, in other words, is skeptical. MarketBeat reported a consensus “Reduce” rating as of September 5, 2026, with analyst price targets sitting well below the current tape. The analysts’ stated concern is pricing pressure on legacy products and the compounding effect of the FDA letters.
The math says margins are recovering and new products are filling the gap left by BAQSIMI’s pricing headwinds. The mood says the pile-up of bad news in a single quarter is not coincidence, it is a pattern worth discounting. Both readings are internally consistent, which is precisely why the gap between them is so wide.
What the filing cannot tell us yet
The Warning Letter at the IMS facility is the least quantifiable risk. Manufacturing remediation timelines are notoriously hard to predict, and the FDA can escalate a Warning Letter to an import alert or a consent decree if it finds the response inadequate. The dossier does not contain the company’s formal response, so the severity of the underlying violations remains opaque. That uncertainty is real, and we state it plainly.
AMP-109, a proprietary oncology peptide that showed strong tumor inhibition in an early study as of September 2026, and a GLP-1 generic called AMP-018 expected in 2027, represent the next layer of the pipeline. Neither has filed data sufficient to anchor a revenue estimate, so they are options, not guarantees.
The filed record presents two coherent readings simultaneously: the quarterly numbers are better than the annual trend implied, the new product engine is working, and the valuation gap is historically wide. Against that sits a $100 million cash outflow, a delayed biosimilar, and a manufacturing facility under federal scrutiny. Which reading prevails depends almost entirely on how the next two FDA interactions resolve, and those answers are not in any filing yet.
Reading the numbers
- $183.9 million Q2 2026 revenue (filed in the 10-Q for the quarter ended June 30, 2026). What it is: total sales for the three months ended June 30. What it means here: revenue is growing again after a full-year decline in 2025. Everyday version: a shop that took in $175 last spring now takes in $184, with newer, higher-priced items driving the difference.
- 51% gross margin in Q2 2026 (same 10-Q). What it is: of every dollar of sales, 51 cents remained after paying to make and source the products. What it means here: new launches carry better economics than the legacy generics they are replacing. Everyday version: a bakery that used to keep 50 cents of every dollar after ingredients now keeps 51, because the new specialty loaf costs the same to bake but sells for more.
- P/E of 11.3 vs. decade median of 19.4 (BullScope valuation model, calculated from trailing-twelve-month GAAP EPS as of June 30, 2026). What it is: the price-to-earnings multiple is the price tag per dollar of annual profit. A multiple of 11.3 means the market pays $11.30 for each dollar Amphastar earns; the historical median is $19.40. What it means here: the stock is priced well below its own norm, which either signals a bargain or a warning. Everyday version: a coffee cart that historically sold for 19 times its annual profit is now on offer at 11 times, because buyers are worried about something.
- $100 million milestone payment to Eli Lilly (disclosed in the Q2 2026 earnings release). What it is: a contractual payment triggered when BAQSIMI cumulative sales crossed a set threshold, owed to the seller of the asset. What it means here: it is a real cash outflow in Q3 2026, larger than a typical quarter’s earnings. Everyday version: a family buys a house with a clause that if rental income ever tops a certain level, they owe the prior owner a $100,000 bonus, and that moment just arrived.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- Amphastar Q2 2026 earnings release (PR Newswire)
- Q2 2026 earnings call transcript (Motley Fool)
- FDA approval announcement for ipratropium bromide HFA (BioSpace)
- Analyst consensus “Reduce” rating, September 5, 2026 (MarketBeat)
- Weekly recap: Q2 growth, BAQSIMI milestone, IMS warning (TradingView)
